Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenues		$ 104,824	$ 77,902	$ 221,316	$ 118,965
Collaboration expense to Pfizer		22,418	8,565	40,434	13,826
Selling, general and administrative	[1]	84,259	58,781	163,291	119,993
Research and development		26,916	26,280	50,806	57,160
Total operating costs and expenses		138,535	96,248	264,388	194,633
Loss from operations		(33,711)	(18,346)	(43,072)	(75,668)
Interest expense	[2]	4,813	3,494	9,013	6,999
Interest income		(1,018)	(100)	(1,504)	(178)
Loss before income taxes		(37,506)	(21,740)	(50,581)	(82,489)
Income tax expense (benefit)		8,113	(149)	16,277	762
Net loss and comprehensive loss		(45,619)	(21,591)	(66,858)	(83,251)
Net loss and comprehensive loss		$ (45,619)	$ (21,591)	$ (66,858)	$ (83,251)
Net loss per common share - basic (in USD per share)		$ (0.47)	$ (0.23)	$ (0.70)	$ (0.90)
Net loss per common share - diluted (in USD per share)		$ (0.47)	$ (0.23)	$ (0.70)	$ (0.90)
Weighted average common shares outstanding - basic (in shares)		96,211,190	92,355,150	95,801,991	92,019,987
Weighted average common shares outstanding - diluted (in shares)		96,211,190	92,355,150	95,801,991	92,019,987
Product revenue, net
Total revenues		$ 49,947	$ 21,063	$ 91,298	$ 32,617
Cost of product revenue		4,942	2,622	9,857	3,654
Pfizer collaboration revenue
Total revenues		54,577	25,172	79,718	54,681
Accord license revenue
Total revenues		0	0	50,000	0
Richter license and milestone revenue
Total revenues		$ 300	$ 31,667	$ 300	$ 31,667

[1] Includes $1,241 and $2,404 of related party expense (inclusive of third-party pass-through costs) for the three and six months ended September 30, 2022, respectively. Includes $1,173 and $2,447 of related party expense (inclusive of third-party pass-through costs) for the three and six months ended September 30, 2021, respectively. See Note 5.

[2] Includes $4,813 and $8,445 of interest expense under the Sumitomo Pharma Loan Agreement for the three and six months ended September 30, 2022, respectively. Includes $2,885 and $5,789 of interest expense under the Sumitomo Pharma Loan Agreement for the three and six months ended September 30, 2021, respectively. See Note 5(C).